Abstract
Very recently, an unusual clinical presentation with an altered natural history associated with hepatitis E virus (HEV) infection has emerged in high-income industrialized nations. Although HEV infection does not develop into chronicity in general, viremia can persist for long periods of time in immunocompromised solid organ, bone marrow and stem cell transplant patients. Conceivably, the atypical clinical and virological outcomes in these cases could be related to immunosuppressive chemotherapy, resulting in suboptimal HEV-specific immune responses. In the absence of travel to endemic regions, foodborne autochthonous HEV infection due to viral genotypes 3 and 4 has been implicated in the chronic cases. Presently, pegIFN-α-2a and ribavirin, the commonly used drugs to treat chronic viral hepatitis, are proving very promising in hepatitis E patients. Nevertheless, the most-awaited HEV vaccine could be protective in naïve travelers or high-risk group populations. The mechanisms of establishing chronic HEV infection and the disease severity have hitherto not been clearly understood. Therefore, a comprehensive clinical, virological and molecular study is needed to understand and control the disease.
References
1.
Purcell RH, Emerson SU: Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008;48:494-503.
2.
Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, Reyes GR: Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 1991;185:120-131.
3.
Chandra V, Taneja S, Kalia M, Jameel S: Molecular biology and pathogenesis of hepatitis E virus. J Biosci 2008;33:451-464.
4.
Graff J, Nguyen H, Yu C, Elkins WR, St Claire M, Purcell RH, Emerson SU: The open reading frame 3 gene of hepatitis E virus contains a cis-reactive element and encodes a protein required for infection of macaques. J Virol 2005;79:6680-6689.
5.
Aggarwal R, Naik S: Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol 2009;24:1484-1493.
6.
Clemente-Casares P, Pina S, Buti M, Jardi R, Martin M, Bofill-Mas S, Girones R: Hepatitis E virus epidemiology in industrialized countries. Emerg Infect Dis 2003;9:448-454.
7.
Moal V, Gerolami R, Colson P: First human case of co-infection with two different subtypes of hepatitis E virus. Intervirology 2012;55:484-487.
8.
Motte A, Roquelaure B, Galambrun C, Bernard F, Zandotti C, Colson P: Hepatitis E in three immunocompromised children in southeastern France. J Clin Virol 2012;53:162-166.
9.
Tessé S, Lioure B, Fornecker L, Wendling MJ, Stoll-Keller F, Bigaillon C, Nicand E: Circulation of genotype 4 hepatitis E virus in Europe: first autochthonous hepatitis E infection in France. J Clin Virol 2012;54:197-200.
10.
Gérolami R, Moal V, Picard C, Colson P: Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. J Hepatol 2009;50:622-624.
11.
Pas SD, de Man RA, Mulders C, Balk AH, van Hal PT, Weimar W, Koopmans MP, Osterhaus AD, van der Eijk AA: Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis 2012;18:869-872.
12.
Pischke S, Suneetha PV, Baechlein C, Barg-Hock H, Heim A, Kamar N, Schlue J, Strassburg CP, Lehner F, Raupach R, Bremer B, Magerstedt P, Cornberg M, Seehusen F, Baumgaertner W, Klempnauer J, Izopet J, Manns MP, Grummer B, Wedemeyer H: Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010;16:74-82.
13.
Kamar N, Weclawiak H, Guilbeau-Frugier C, Legrand-Abravanel F, Cointault O, Ribes D, Esposito L, Cardeau-Desangles I, Guitard J, Sallusto F, Muscari F, Peron JM, Alric L, Izopet J, Rostaing L: Hepatitis E virus and the kidney in solid-organ transplant patients. Transplant 2012;93:617-623.
14.
Maylin S, Stephan R, Molina JM, Peraldi MN, Scieux C, Nicand E, Simon F, Delaugerre C: Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised. J Clin Virol 2012;53:346-349.
15.
Halac U, Béland K, Lapierre P, Patey N, Ward P, Brassard J, Houde A, Alvarez F: Chronic hepatitis E infection in children with liver transplantation. Gut 2012;61:597-603.
16.
le Coutre P, Meisel H, Hofmann J, Röcken C, Vuong GL, Neuburger S, Hemmati PG, Dörken B, Arnold R: Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 2009;58:699-702.
17.
Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, Cointault O, Esposito L, Abravanel F, Danjoux M, Durand D, Vinel JP, Izopet J, Rostaing L: Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-817.
18.
Halac U, Béland K, Lapierre P, Patey N, Ward P, Brassard J, Houde A, Alvarez F: Cirrhosis due to chronic hepatitis E infection in a child post-bone marrow transplant. J Pediatr 2012;160:871-874.
19.
Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E, Conti F, Lebray P, Dalton HR, Santella R, Kanaan N, Essig M, Mousson C, Radenne S, Roque-Afonso AM, Izopet J, Rostaing L: Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011;140:1481-1489.
20.
Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KE, Kovari H, Kaiser L, Evison JM, Elzi L, Gurter-De La Fuente V, Jost J, Moradpour D, Abravanel F, Izpopet J, Cavassini M, Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland: Hepatitis E virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis 2011;17:1074-1078.
21.
Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, Koopmans MP: Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008;14:547-553.
22.
Keane F, Gompels M, Bendall R, Drayton R, Jennings L, Black J, Baragwanath G, Lin N, Henley W, Ngui SL, Ijaz S, Dalton H: Hepatitis E virus coinfection in patients with HIV infection. HIV Med 2012;13:83-88.
23.
Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, Bradley DW: Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990;247:1335-1339.
24.
Hakze-van der Honing RW, van Coillie E, Antonis AF, et al: First isolation of hepatitis E virus genotype 4 in Europe through swine surveillance in the Netherlands and Belgium. PLoS One 2011;6:e22673.
25.
Lu L, Li C, Hagedorn CH: Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 2006;16:5-36.
26.
Bouquet J, Tessé S, Lunazzi A, Eloit M, Rose N, Nicand E, Pavio N: Close similarity between sequences of hepatitis E virus recovered from humans and swine, France, 2008-2009. Emerg Infect Dis 2011;17:2018-2025.
27.
Meng XJ, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsareva TS, et al: A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci USA 1997;94:9860-9865.
28.
Pavio N, Meng XJ, Renou C: Zoonotic hepatitis E: animal reservoirs and emerging risks. Vet Res 2010;41:41-46.
29.
De Deus N, Peralta B, Pina S, Allepuz A, Mateu E, Vidal D, et al: Epidemiological study of hepatitis E virus infection in European wild boars (Sus scrofa) in Spain. Vet Microbiol 2008;129:163-170.
30.
Martelli F, Caprioli A, Zengarini M, Marata A, Fiegna C, Di Bartolo I, et al: Detection of hepatitis E virus (HEV) in a demographic managed wild boar (Sus scrofa scrofa) population in Italy. Vet Microbiol 2008;126:74-81.
31.
Colson P, Borentain P, Queyriaux B, Kaba M, Moal V, Gallian P, Heyries L, Raoult D, Gerolami R: Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 2010;202:825-834.
32.
Wichmann O, Schimanski S, Koch J, Kohler M, Rothe C, Plentz A, Jilg W, Stark K: Phylogenetic and case-control study on hepatitis E virus infection in Germany. J Infect Dis 2008;198:1732-1741.
33.
Shukla P, Nguyen HT, Torian U, Engle RE, Faulk K, Dalton HR, Bendall RP, Keane FE, Purcell RH, Emerson SU: Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci USA 2011;108:2438-2443.
34.
Kamar N, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, Izopet J, Rostaing L: Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant 2010;25:2792-2795.
35.
Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, Basse G, Cointault O, Ribes D, Nogier MB, Alric L, Peron JM, Izopet J: Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 2010;139:1612-1618.
36.
Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, et al: Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356:895-903.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
